Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local Tumor Microenvironment Niches Correlate With Survival And Immunotherapy Response In Human Glioblastoma.

bioRxiv : the preprint server for biology·2026
Same author

Retraction Notice to: "CSF1 Restores Innate Immunity After Liver Injury in Mice and Serum Levels Indicate Outcomes of Patients With Acute Liver Failure" Gastroenterology 2015;149:1896-1909.e14.

Gastroenterology·2025
Same author

Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism.

Nature communications·2025
Same author

Author Correction: Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis.

Nature cancer·2024
Same author

Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis.

Nature cancer·2024
Same author

Jeff Pollard (1950-2023).

Nature reviews. Cancer·2023

Related Experiment Video

Updated: Mar 3, 2026

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
09:23

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Published on: October 20, 2016

14.9K

Repolarizing macrophages improves breast cancer therapy.

Luca Cassetta1, Jeffrey W Pollard1,2

  • 1MRC Centre for Reproductive Health, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh EH16 4TJ, UK.

Cell Research
|April 22, 2017
PubMed
Summary

A novel HDAC inhibitor, TMP195, reprograms tumor-associated macrophages (TAMs) in breast cancer. This reprogramming enhances CD8 T cell responses, promoting an anti-tumoral immune response for potential cancer therapy.

More Related Videos

Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis
07:47

Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis

Published on: June 26, 2016

10.2K
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

8.2K

Related Experiment Videos

Last Updated: Mar 3, 2026

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
09:23

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Published on: October 20, 2016

14.9K
Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis
07:47

Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis

Published on: June 26, 2016

10.2K
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

8.2K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Tumor-associated macrophages (TAMs) play a crucial role in promoting breast cancer progression and metastasis.
  • Targeting TAMs for reprogramming represents a promising strategy in preclinical cancer research.

Purpose of the Study:

  • To investigate the effects of a novel HDAC Class IIa inhibitor, TMP195, on TAMs in the context of breast cancer.
  • To determine if TMP195 can reprogram TAMs to elicit an anti-tumoral immune response.

Main Methods:

  • Utilized TMP195, a novel HDAC Class IIa inhibitor.
  • Studied the reprogramming of monocytes and macrophages within the tumor microenvironment.
  • Assessed the impact on CD8 T cell-mediated anti-tumoral immunity.

Main Results:

  • TMP195 demonstrated the ability to reprogram monocytes and macrophages within the tumor.
  • Reprogrammed cells were capable of sustaining a robust CD8 T cell-mediated anti-tumoral immune response.
  • These findings suggest a mechanism for enhancing anti-cancer immunity through TAM modulation.

Conclusions:

  • The HDAC Class IIa inhibitor TMP195 shows potential in reprogramming TAMs.
  • This reprogramming can foster a potent CD8 T cell-driven anti-tumoral effect in breast cancer.
  • TMP195 represents a potential therapeutic agent for modulating the tumor immune microenvironment.